Thursday, 27 January 2022
  
Login

Australia's most trusted
source of pharma news

Thursday, 27 January 2022
Ascott
Ascott
Omicron-busting vax on the way

The race is on with mRNA Covid vaccine developers Pfizer and Moderna each commencing trials of an  Omicron-specific jab, as data continues to show the variant's ability to evade immunity.

Who's on the HR hot list?
The most influential leaders contributing to change
TODAY
Janssen boss: the time is now
Fearless advocate for change sets her sights on HTA reform
TODAY
Flexible work 2022-style
The definition of a flexible workplace gets a makeover
TODAY
MSD names new Aussie boss
Leader heads Down Under with a mission to expand access
24 January
Why Omicron spreads so fast
Viral load isn't the answer, two new studies reveal
24 January
Aussie expat is new Vertex boss
First task, a controversial reimbursement battle
21 January
Who's our top pharma employer?
One company makes prestigious list six years straight
21 January
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (10)

Sales & Customer Relations (29)

Access & Reimbursement (1)

Clinical & Medical, R&D (16)

Regulatory, Pharmacovigilance & QA (6)

Other (17)

What is a medicine, anyway?
NMP Review told it must redefine the basics
TODAY
Sanofi cancer drug expands
TGA green lights new indications for PD-1 inhibitor
TODAY
Kid vax sparks death threats
Nervous GPs pull out of under 12s COVID-19 vax program
25 January
Aussie innovators join forces
New partnership will slash time to produce RWE by years
25 January
Top PBS earners revealed
Who earned the most from the PBS in the 2021 financial year?
25 January
Bayer boss on tackling change
MA board contender on making a real and lasting difference
25 January
Novartis creates new lead role
Ensuring accountability on diversity and inclusion objectives
25 January
Pill Hill still the place to be
Sanofi clocks up 15 years at Macquarie Park with a new membership
25 January
Rivals give Pfizer a back pat
New Covid antiviral treatment hailed as 'breathtaking'
24 January
AbbVie v Sanofi in PBS win
Green light sees companies level up in eczema market
24 January
Review caves in to pressure
About-face sees 'secret' medicines policy submissions made public
24 January
Influx of new medicines
Two out of five new TGA approved products sponsored by MSD
24 January APPROVALS
Merck pips Novartis in MET race
Competition heats up as both companies eye the NSCLC market
21 January
Aust price cuts not the worst
Downward pressure on drug costs is harsher elsewhere
21 January
pif 20K
pif 20K
Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.